EXCALIBER RRMM

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

What's the purpose of the trial?

This is a multicenter, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Trial status

Accepting patients

Phase
Phase 3
Enrollment
864
Last Updated
1 month ago
Patient Screener

Participating Centers

There are 32 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Bortezomib
  • Daratumumab
  • Dexamethasone
  • Iberdomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Iberdomide + Daratumumab + Dexamethasone

Accepting patients

Daratumumab + Bortezomib + Dexamethasone

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.